INTRODUCTION {#sec1-1}
============

Children routinely undergo painful and traumatic diagnostic and therapeutic procedures in Emergency Department (ED), which include fracture reduction, incision and drainage of abscesses, suturing of lacerations, or foreign bodies extraction.

The American College of Emergency Physicians defines procedural sedation as a method to "induce a state that allows the patient to tolerate unpleasant procedures while maintaining cardiorespiratory function independently and continuously."\[[@ref1]\]

Procedural sedation has become the standard practice in the majority of EDs using different drugs with ketamine being the most commonly used drug. The first publications of ketamine use in children by non-anesthetists in EDs in the US was in the early 1990s.\[[@ref2][@ref3][@ref4][@ref5]\]

The administration of procedure sedation requires experienced physicians with comprehensive knowledge of the drugs used and skills in pediatric airway management and resuscitation. The adverse event rate for procedural sedation and analgesia (PSA) performed by pediatric emergency physicians reported as 2.3% with no serious complications noted.\[[@ref3]\]

Side-effects of Ketamine include nausea, vomiting, hypersalivation and agitation/hallucination (emergence reaction), but its safety profile has been found to be excellent in various settings.\[[@ref4][@ref5]\] Ketamine has been reviewed extensively and shown to be extremely safe for use in Pediatric Emergency Department (PED).\[[@ref6][@ref7][@ref8][@ref9][@ref10]\]

According to the literature review, there are no reports of procedural sedation in pediatric emergency from Saudi Arabia or middle east-north Africa region and we believe that we will present the first report from this area.

MATERIALS AND METHODS {#sec1-2}
=====================

Study design {#sec2-1}
------------

Retrospective cross-sectional study of all cases underwent PSA for painful procedures in Pediatric Emergency at King Khalid University Hospital (KKUH) from December 2005 to July 2008.

Study setting and population {#sec2-2}
----------------------------

This study was performed in the PED of a tertiary care teaching hospital with an average of 42,000 patient visits/year of different level of acuity level. Patients receiving PSA in the ED December 2005-July 2008 by the emergency physicians were included.

Study protocol {#sec2-3}
--------------

Procedural sedation recording sheet were reviewed and data were abstracted for all children who underwent any painful procedure from December 2005 to July 2008. It is the standard of care at our center to have the procedural sedation performed in the resuscitation room where full pediatric resuscitation facilities were available. A trained nurse and pediatrician with advanced airway and pediatric resuscitation skills were present to perform and supervise the sedation while another physician performed the procedure. Patients were monitored with continuous pulse-oximeter and cardiorespiratory monitors. Vital signs measurements were recorded every 5 min by a nurse with a complete presedation assessment sheet. The nurse remains with the patient from the time of administration of the sedation drug to the time the patient was ready for discharge. After completion of the procedure, patients were observed and monitored in the resuscitation room for 30 min after drug administration and then moved to the dedicated observation bed. Upon complete recovery with the normal level of consciousness, patients were discharged.

Measurements/data collection {#sec2-4}
----------------------------

For all patients receiving PSA in this ED, procedural sedation sheet, which become part of the medical record, are automatically generated. Nurses and physicians caring for the patients complete these sheets. Data pertaining to procedure type, drugs and doses used, vital signs, adverse events and length of stay in the ED were extracted from the procedural sedation sheet and recorded in a separate data collection sheets made for this study. Further chart review done to confirm the data. Descriptive Statistical analysis was performed using the statistical package for the social sciences software.

RESULTS {#sec1-3}
=======

During the study period, 183 patients received PSA in the PED. Four patients were excluded from the analysis because certain documentations were missing in their medical records. A total of 179 patients were analyzed. The age ranged from 4 months to 13 years (mean 6 years) with 66% of the patients being male.

Different drug combinations were used as per the patient\'s condition and the treating physician\'s preference \[[Table 1](#T1){ref-type="table"}\]. Ketamine was used in 90% of cases. Nearly 34.5% were pretreated with Atropine. The doses of ketamine ranged from 0.07 to 3 mg/kg with a mean of 1.2 mg/kg.

###### 

Drugs used in the procedural sedation

![](JETS-7-186-g001)

Fasting guidelines according to application of the American college of emergency physicians recommendation were met in 165 patients (92.2%).

The most frequent indications for sedation were Fracture and Dislocation Reduction (60.9%), Repair of fingertip injuries (11.7%) and abscess drainage (11.7%) \[[Table 2](#T2){ref-type="table"}\]. 10 patients (5.6%) developed adverse events \[[Table 3](#T3){ref-type="table"}\].

###### 

The indications of procedure sedation

![](JETS-7-186-g002)

###### 

Description of patients developed adverse effects

![](JETS-7-186-g003)

Of those adverse effects vomiting was the most common occurring in six patients (60%) during the recovery period. Three of these patients had met the fasting guidelines and two did not. In one patient, the fasting status was not documented. Respiratory adverse events were observed in one patient who had apnea and oxygen desaturation to 80% in room air at 5 min after the start of sedation, however he was managed by bag mask ventilation with 100% oxygen and recovered within a few seconds while the procedure continued \[patient 7 in [Table 3](#T3){ref-type="table"}\]. Two patients (1.2%) developed emergence reaction during recovery. One was a 9-year-old girl who received ketamine and developed emergence reaction during her recovery. She required treatment by midazolam \[patient 8 [Table 3](#T3){ref-type="table"}\]. The other was an 11-year-old male who received ketamine and atropine who required no treatment for the emergence reaction \[patient 9 [Table 3](#T3){ref-type="table"}\].

One patient developed jerky movement and shivering during the sedation with ketamine. She was managed by 100% oxygen and intravenous (IV) midazolam \[patient number 10 [Table 3](#T3){ref-type="table"}\].

All the procedures were successfully completed without any co morbidity and none of the patients were admitted to the hospital secondary to adverse events associated with PSA.

The length of stay in the ED was calculated from the start of procedural sedation until the time patients left the ED. It was ranging from 28 to 320 min (mean 110 min).

DISCUSSION {#sec1-4}
==========

In our series, the overall incidence of adverse events (5.6%) is comparable to the reported adverse effects in the literatures (2.3-4.5%).\[[@ref3][@ref11]\] and however less than what reported by Roback *et al*. (17%).\[[@ref12]\]

Vomiting is the most common adverse effect (60%) and despite variations in fasting recommendations, there were no episodes of aspiration. Vomiting incidence ranges from 0% to 43% in reviewed literature with rare incidence of pulmonary aspiration of gastric content.\[[@ref13],[@ref14]\]

None of the recent case series as well as our study have reported any episodes of apnea requiring intervention other than supplemental oxygen or brief manual ventilation assistance. As noted in previous studies, laryngospasm is very rare with incidence of 0.017%.\[[@ref4]\] Whereas we did not encounter any case of laryngospasm, which may be due to small sample size of our study.

The overall incidence of respiratory adverse events and vomiting in our series (3.9%) is less than that of Pitetti *et al*. (17.9%)\[[@ref9]\] and Roback *et al*. (15%)\[[@ref12]\] but higher than that found by Peña and Krauss (2.3%).\[[@ref3]\] This could be due to the relatively smaller number of patients in our study.

The incidence of emergence phenomena is 0-10% and rare in children under 10 years old.\[[@ref12]\]

In this study, two patients (1%) developed Emergence phenomena during recovery. Both were above 9 years and received ketamine without midazolam. Previous studies have commented on the inability of midazolam to diminish emergence reactions associated with ketamine sedation. A study by Wathen *et al*. commented further that in their 266 patients, those who received ketamine/midazolam were more likely to have desaturation but less likely to vomit than those receiving ketamine alone.\[[@ref11]\]

In our study, the majority of patients received ketamine without midazolam and only two developed emergence phenomena and none of the twelve patients who received midazolam had any adverse event.

Seizure activity with ketamine has been rarely reported and it is said to have anticonvulsant properties.\[[@ref12]\]

One patient in our series was reported to have jerky movement and shivering (but not generalized tonic clonic movement). This was thought to be seizure activity and the child was given IV midazolam, which controlled the abnormal movements. It is quite possible that the "shaking episodes" described to have occurred in this patient may have been exaggerated muscular hyper tonicity rather than true seizure activity.

Muscular hypertonicity has been reported to occur commonly with ketamine sedation and was not observed in this study, this may be due to underreporting this effect by the physician and nurses as this specific effect is not mentioned in the adverse effect box in the sedation sheet.

We did not encounter any cardiovascular adverse events. These findings are consistent with those of Peña and Krauss (one episode of bradycardia in 1,180 sedations; 0.001%)\[[@ref3]\] and Pitetti *et al*. (two episodes of hypotension in 1,244 sedations; 0.002%).\[[@ref9]\]

Tachycardia and hypertension, which was noted in the vital signs are expected effects of ketamine sedation and were not recorded as complications.

We reported a longer length of stay in the ED compared with that reported by several literatures ranging from 25 to 101 min. This time is defined as the time from injection of ketamine to actual departure from the ED. Green\'s\[[@ref15]\] and Dachs\[[@ref16]\] recorded time to "ready for discharge," a better measure of sedation recovery time as it would exclude department management issues such as completion of paperwork and organization of transport. Our longer time could be explained by the time needed for parents to arrange for transportation, completion of consultation and paperwork processing for admitted patients. When we consider the length of stay from the injection time to the time patients were ready for discharge we got a shorter length of stay of 98 min (15-255 min). When we excluded patient who was admitted from the analysis the median discharge time was 95 min (28-210 min) and with further exclusion of those who had adverse events as it prolonged the observation time, the mean time to discharge was 82 min which is comparable to what reported by McGlone *et al*. (85 min)\[[@ref17]\] and Acworth *et al*. (98 min)\[[@ref18]\] however less than those reported by Ellis *et al*. (101 min).\[[@ref2]\]

In our series, there was no relation between the dose of ketamine used and the incidence of adverse events. Green found that there was no clinical or statistical difference in the time to discharge, adverse events, emesis, recovery agitation, time to discharge and adequacy of sedation in relation to ketamine dose, though there was a trend toward improved sedation adequacy with increasing dose.\[[@ref19]\]

Limitations {#sec2-5}
-----------

Our study had limitations. The retrospective nature of the study limited the number of variables that we were able to explore. The relatively small number of patients from a single center limited the ability to do subgroups analysis of the different drug combinations used and adverse events.

CONCLUSION {#sec1-5}
==========

Our experience in pediatric PSA at KKUH is comparable to reported data from other centers. IV Ketamine is a consistently effective method of producing a rapid, brief period of profound sedation and analgesia in children in the ED with no major side-effects noted in our experience.
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